Regulations.gov document
Final Response from FDA CDER to Boehringer Ingelheim Pharmaceuticals (BIPI)
Other · FDA-2012-P-1072 · posted Jun 20, 2023
Key facts
| Document ID | FDA-2012-P-1072-0006 |
|---|---|
| Title | Final Response from FDA CDER to Boehringer Ingelheim Pharmaceuticals (BIPI) |
| Document type | Other |
| Subtype | Response(s) |
| Agency | FDA |
| Docket | FDA-2012-P-1072 |
| Posted | Jun 20, 2023 |
| Comment period opens | Jun 20, 2023 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: